Lebrikizumab Improves Itch and Lesions in AD Patients Who Discontinued Dupilumab: Dr. Linda Stein Gold Reviews the Data October 29, 2024
LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Achieved Higher Treatment Targets October 28, 2024